Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Dec 12, 2022 (4 years ago)

Rifampin Capsules USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: Failure observed in related substance testing during long term stability study.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Rifampin Capsules USP, 300 mg, 30-count bottle; Rx Only, Manufactured for: Lupin Pharmaceuticals Baltimore, Maryland 21202, Manufactured by: Lupin Limited Aurangabad 431 210 India. NDC 68180-659-06

Affected NDC 68180-0659-06

Compare with the code on your package — it is the most precise check available.

Drug: Rifampin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
rifampin
NDC 68180-0659
300 mg/1 Capsule
Oral
Lupin Pharmaceuticals, Inc. Rx
Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-659-06
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0100-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Rifampin recalls

See all

Other recalls by Lupin Pharmaceuticals Inc.

All 2022 recalls